eCite Digital Repository

Incretin-based therapies

Citation

Bereznicki, L, Incretin-based therapies, Australian Pharmacist, 29, (6) pp. 508-513. ISSN 0728-4632 (2010) [Professional, Non Refereed Article]


Preview
PDF
Restricted - Request a copy
354Kb
  

Copyright Statement

Copyright 2010 Pharmaceutical Society of Australia

Official URL: http://www.psa.org.au/

Abstract

The number of Australians with type 2 diabetes mellitus (T2DM) has tripled since 1981 and continues to increase. It is projected that 1.6 million Australians will have type 2 diabetes by 2030. Because T2DM frequently co-exists with excess weight, hypertension and dyslipidaemia, health professionals involved in the management of diabetes should focus on blood pressure management, cholesterol lowering and consider the use of lowdose aspirin for primary prevention (although this is now contentious) as means of reducing cardiovascular risk, in addition to targeting glycaemic control

Item Details

Item Type:Professional, Non Refereed Article
Keywords:Incretin based therapies, oral inhibitors, receptor agonists, clinical trials, diabetes
Research Division:Medical and Health Sciences
Research Group:Pharmacology and Pharmaceutical Sciences
Research Field:Pharmacology and Pharmaceutical Sciences not elsewhere classified
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Diabetes
Author:Bereznicki, L (Professor Luke Bereznicki)
ID Code:64292
Year Published:2010
Deposited By:Pharmacy
Deposited On:2010-07-14
Last Modified:2011-06-10
Downloads:1 View Download Statistics

Repository Staff Only: item control page